









市场行情
/
股票
/
nasdaq-crbp
/

Corbus Pharmaceuticals Holdings Inc

CRBP

8.120USD

+0.020+0.25%

收盘 12/19, 16:00（美东）报价延迟15分钟

101.78M总市值

亏损市盈率 TTM



Corbus Pharmaceuticals Holdings Inc

8.120

+0.020+0.25%

概览公司财务分析

概览

公司

财务

分析

关于 Corbus Pharmaceuticals Holdings Inc 公司

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

Corbus Pharmaceuticals Holdings Inc简介



公司代码CRBP

公司名称Corbus Pharmaceuticals Holdings Inc

上市日期Oct 24, 2014

CEOCohen (Yuval)

员工数量28

证券类型Ordinary Share

年结日Oct 24

公司地址500 River Ridge Drive

城市NORWOOD

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02062

电话16179630103

网址https://www.corbuspharma.com/

公司代码CRBP

上市日期Oct 24, 2014

CEOCohen (Yuval)

Corbus Pharmaceuticals Holdings Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Sean F. Moran, CPA

Chief Financial Officer

15.68K

Dr. Yuval Cohen, Ph.D.

Chief Executive Officer, Director

14.63K

Mr. Alan F. Holmer, J.D.

Independent Director

7.85K

+157.58%

Dr. Dominic Smethurst

Chief Medical Officer

6.11K

-92.09%

Dr. Yong Ben, M.D., Ph.D.

Independent Director

4.80K

Ms. Rachelle Suzanne Jacques

Independent Chairman of the Board

4.80K

Dr. Anne Altmeyer, Ph.D.

Independent Director

3.41K

Dr. Ian Hodgson

Chief Operating Officer

1.23K

Dr. John Kenneth Jenkins, M.D.

Independent Director

Mr. Winston W. Kung

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Sean F. Moran, CPA

Chief Financial Officer

15.68K

Dr. Yuval Cohen, Ph.D.

Chief Executive Officer, Director

14.63K

Mr. Alan F. Holmer, J.D.

Independent Director

7.85K

+157.58%

Dr. Dominic Smethurst

Chief Medical Officer

6.11K

-92.09%

Dr. Yong Ben, M.D., Ph.D.

Independent Director

4.80K

Ms. Rachelle Suzanne Jacques

Independent Chairman of the Board

4.80K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月2日周二

持股股东

股东类型

持股股东

占比

Cormorant Asset Management, LP

13.36%

OrbiMed Advisors, LLC

6.68%

Octagon Capital Advisors LP

6.35%

Citadel Advisors LLC

5.59%

The Vanguard Group, Inc.

3.49%

其他

64.54%

持股股东

占比

Cormorant Asset Management, LP

13.36%

OrbiMed Advisors, LLC

6.68%

Octagon Capital Advisors LP

6.35%

Citadel Advisors LLC

5.59%

The Vanguard Group, Inc.

3.49%

其他

64.54%

股东类型

持股股东

占比

Hedge Fund

32.79%

Investment Advisor

7.70%

Private Equity

6.68%

Investment Advisor/Hedge Fund

6.14%

Venture Capital

2.45%

Research Firm

1.93%

Bank and Trust

1.16%

Individual Investor

0.43%

其他

40.72%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

244

9.91M

80.52%

+983.33K

2025Q3

247

9.76M

113.59%

-275.42K

2025Q2

241

10.04M

128.17%

-1.37M

2025Q1

238

11.57M

122.09%

-3.37M

2024Q4

247

12.14M

125.11%

-689.52K

2024Q3

235

12.83M

99.91%

+494.88K

2024Q2

203

12.32M

76.88%

+2.31M

2024Q1

161

10.21M

42.49%

+5.75M

2023Q4

129

1.15M

32.26%

+195.69K

2023Q3

138

958.46K

32.32%

+8.70K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Cormorant Asset Management, LP

2.38M

19.38%

Jun 30, 2025

OrbiMed Advisors, LLC

1.17M

9.57%

Jun 30, 2025

Octagon Capital Advisors LP

1.11M

9.1%

Jun 30, 2025

The Vanguard Group, Inc.

599.50K

4.89%

-72.56K

-10.80%

Jun 30, 2025

Prosight Capital

579.89K

4.73%

+4.76K

+0.83%

Jun 30, 2025

Exome Asset Management LLC

277.32K

2.26%

-12.37K

-4.27%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

336.42K

2.75%

-454.48K

-57.46%

Jun 30, 2025

Comerica, Inc.

200.00K

1.63%

Jun 30, 2025

Armistice Capital LLC

192.00K

1.57%

-58.00K

-23.20%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.03%

Avantis US Small Cap Equity ETF

0.01%

Pacer WealthShield ETF

Harbor Health Care ETF

ProShares Hedge Replication ETF

Tema Oncology ETF

Schwab U.S. Broad Market ETF

iShares Core S&P Total U.S. Stock Market ETF

Vanguard US Momentum Factor ETF

Fidelity Enhanced Small Cap ETF

iShares Micro-Cap ETF

占比0.03%

Avantis US Small Cap Equity ETF

占比0.01%

Pacer WealthShield ETF

占比0%

Harbor Health Care ETF

占比0%

ProShares Hedge Replication ETF

占比0%

Tema Oncology ETF

占比0%

Schwab U.S. Broad Market ETF

占比0%

iShares Core S&P Total U.S. Stock Market ETF

占比0%

Vanguard US Momentum Factor ETF

占比0%

Fidelity Enhanced Small Cap ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

公告日期

类型

比率

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

Feb 13, 2023

Merger

30→1

常见问题

Corbus Pharmaceuticals Holdings Inc的前五大股东是谁？



Corbus Pharmaceuticals Holdings Inc 的前五大股东如下：
Cormorant Asset Management, LP持有股份：2.38M，占总股份比例：19.38%。
OrbiMed Advisors, LLC持有股份：1.17M，占总股份比例：9.57%。
Octagon Capital Advisors LP持有股份：1.11M，占总股份比例：9.10%。
The Vanguard Group, Inc.持有股份：599.50K，占总股份比例：4.89%。
Prosight Capital持有股份：579.89K，占总股份比例：4.73%。